Table 3.
Subject demographics of the onapristone extended release (ONA-ER) pooled safety analysis (n = 88)
Demographic | n (%) |
---|---|
Female | 52 (59.1) |
Male | 36 (40.9) |
Age, median (range) | 68.0 (36–89) |
> 65 years | 61 (69.3) |
Ethnicity | |
African ancestry | 0 (0) |
Asian | 0 (0) |
Caucasian | 87 (98.9) |
Unknown | 1 (0.9) |
Tumor type | |
Endometrial/uterine | 19 (21.5) |
Ovarian | 12 (13.6) |
Breast | 21 (23.9) |
Prostate | 36 (41.0) |
Metastases | |
Liver | 25 (28.4) |
Bone | 42 (47.7) |
Treatment | |
ONA-ER | 73 (83.0) |
ONA-ER+ abiraterone | 15 (17.0) |